Published on in CHOP News
CHOP researchers have identified BAFF as a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A.
Published on in CHOP News
CHOP researchers identified an in vivo role for activated protein C (APC), which could potentially be exploited for future hemophilia A treatments.
Published on in Community Benefit Report
CHOP volunteers make camp a reality for many kids with special medical needs. They not only keep them healthy, but they also take part of the activities and enjoy seeing kids being kids.
Published on in CHOP News
A laboratory study may set the stage for a new preventive treatment for hemophilia patients who now develop antibodies to the standard treatment and then require a bypass therapy.
Published on in CHOP News
CHOP breakthrough helps scientists edge closer to defeating a longtime enemy of human health: hemophilia, the inability to form blood clots.
Published on in CHOP News
A team of gene therapy researchers has reported on a highly active gene variant that achieved sustained factor levels in 10 adults, with no adverse effects.
Published on in CHOP News
A clinical trial of a gene therapy for hemophilia B is allowing patients to avoid painful, disabling internal bleeds.
Published on in CHOP News
Three CHOP researchers recently won grants for their work on hemophilia from the Bayer Hemophilia Awards Program.
Published on in CHOP News, International Update
In a clinical trial led by a CHOP researcher, adult patients with hemophilia B were able to pursue daily activities without disabling bleeds.
Published on in Beyond Blood
Von Willebrand disease (VWD) is a bleeding disorder caused by having too little von Willebrand factor (VWF) protein or VWF that doesn’t work well.